Cargando…

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

PURPOSE: To assess safety and efficacy of saxagliptin in older patients with type 2 diabetes mellitus (T2DM). PATIENTS AND METHODS: This was a post hoc analysis of pooled data from older patients (≥65 years of age) from five 24-week phase III trials: three studies of saxagliptin versus placebo as an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karyekar, Chetan S, Ravichandran, Shoba, Allen, Elsie, Fleming, Douglas, Frederich, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632630/ https://www.ncbi.nlm.nih.gov/pubmed/23626461 http://dx.doi.org/10.2147/CIA.S41246

Ejemplares similares

Clinically relevant reductions in HbA(1c) without hypoglycaemia: results across four studies of saxagliptin
por: Karyekar, C S, et al.
Publicado: (2013)

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
por: Iqbal, Nayyar, et al.
Publicado: (2014)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
por: Frederich, Robert, et al.
Publicado: (2012)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Tolerability of Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes: Results from 6 Phase III Studies
por: Davidson, Jaime A.
Publicado: (2014)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients
por: Garg, Rajesh, et al.
Publicado: (2017)

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
por: Villar, Miriam Méndez-del, et al.
Publicado: (2017)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Liu, Hao, et al.
Publicado: (2016)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
por: Li, Chun-Jun, et al.
Publicado: (2014)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
por: Tao, Tao, et al.
Publicado: (2018)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial
por: Lu, Chieh‐Hsiang, et al.
Publicado: (2015)

Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial
por: Li, Feng-fei, et al.
Publicado: (2016)

Absence of diabetic retinopathy in a patient who has had diabetes mellitus for 69 years, and inadequate glycemic control: case presentation
por: Esteves, Jorge, et al.
Publicado: (2009)

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
por: Chacra, A R, et al.
Publicado: (2009)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas
por: Hsieh, Sheng-Hwu, et al.
Publicado: (2010)

Characteristics, treatment patterns, and glycemic control of older type 2 diabetes mellitus patients in China
por: Cai, Xiao-Ling, et al.
Publicado: (2021)

Impact of baseline characteristics on glycemic effects of add‐on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus
por: Fang, Hui, et al.
Publicado: (2020)

Absence of diabetic retinopathy in a patient who has had diabetes mellitus for 69 years, and inadequate glycemic control: case presentation: response
por: Raman, Rajiv, et al.
Publicado: (2010)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis
por: Jingfan, Zhang, et al.
Publicado: (2019)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Inadequate Vitamin C Status in Prediabetes and Type 2 Diabetes Mellitus: Associations with Glycaemic Control, Obesity, and Smoking
por: Wilson, Renée, et al.
Publicado: (2017)

A Randomized Controlled Trial of an Internet-Based Mentoring Program for Type 1 Diabetes Patients with Inadequate Glycemic Control
por: Suh, Sunghwan, et al.
Publicado: (2014)

Delay Of Insulin Addition To Oral Combination Therapy Despite Inadequate Glycemic Control: Delay of Insulin Therapy
por: Nichols, Gregory A., et al.
Publicado: (2007)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
por: Farr, Amanda M, et al.
Publicado: (2016)

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
por: Fonseca, Vivian A., et al.
Publicado: (2008)

Oscillatory pattern of glycemic control in patients with diabetes mellitus
por: Vasquez-Muñoz, Manuel, et al.
Publicado: (2021)

Characterization of the gut microbiota in diabetes mellitus II patients with adequate and inadequate metabolic control
por: Hamasaki-Matos, Angie Joyce, et al.
Publicado: (2021)

Efficacy of pioglitazone on glycemic control and carotid intima‐media thickness in type 2 diabetes patients with inadequate insulin therapy
por: Yasunari, Eisuke, et al.
Publicado: (2011)

Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial
por: Hao, Zhaohu, et al.
Publicado: (2018)

Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
por: Budoff, Matthew J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1hg4ohgnm2b0gf68drrgh229pr